Protein & Cell

, Volume 2, Issue 11, pp 899–905

Parkinson disease drug screening based on the interaction between D2 dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis

  • Zheng Zhou
  • Jun-Ming Liao
  • Peng Zhang
  • Jun-Bao Fan
  • Jie Chen
  • Yi Liang
Communication

DOI: 10.1007/s13238-011-1096-0

Cite this article as:
Zhou, Z., Liao, JM., Zhang, P. et al. Protein Cell (2011) 2: 899. doi:10.1007/s13238-011-1096-0

Abstract

Parkinson’s disease is the second most common neurodegenerative disease in the world. Beta-arrestin-2 has been reported to be an important protein involved in D2 dopamine receptor desensitization, which is essential to Parkinson’s disease. Moreover, the potential value of pharmacological inactivation of G protein-coupled receptor kinase or arrestin in the treatment of patients with Parkinson’s disease has recently been shown. We studied the interaction between D2 dopamine receptor and beta-arrestin-2 and the pharmacological regulation of chemical compounds on such interaction using capillary zone electrophoresis. The results from screening more than 40 compounds revealed three compounds that remarkably inhibit the beta-arrestin-2/D2 dopamine receptor interaction among them. These compounds are promising therapies for Parkinson’s disease, and the method used in this study has great potential for application in large-scale drug screening and evaluation.

Keywords

drug screening D2 dopamine receptor beta-arrestin-2 capillary zone electrophoresis protein-protein interaction Parkinson’s disease 

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Zheng Zhou
    • 1
  • Jun-Ming Liao
    • 1
  • Peng Zhang
    • 1
  • Jun-Bao Fan
    • 1
  • Jie Chen
    • 1
  • Yi Liang
    • 1
  1. 1.State Key Laboratory of Virology, College of Life SciencesWuhan UniversityWuhanChina

Personalised recommendations